Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06271837 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors

Name: A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors — clinical trial record (NCT06271837)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhasePhase 2

SponsorAstraZeneca

Started2024-02-22

View on ClinicalTrials.gov ↗

This is an open-label, multicenter, Phase II study to evaluate the efficacy and safety of trastuzumab deruxtecan as monotherapy or in combination with anti-cancer agents for the treatment in locally advanced, unresectable, or metastatic patients with selected HER2-expressing solid tumors which are not eligible for curative therapy.

Amendment history 1 change detected by DataLookout

2026-09-04

Primary completion pushed: 2025-11-28 → 2027-02-10

Trial Details

NCT Number	NCT06271837
Lead Sponsor	AstraZeneca Collaborators: Daiichi Sankyo Co., Ltd.
Conditions	Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)
Enrollment	127 participants
Start Date	2024-02-22
Primary Completion	2027-02-10 (estimated)
Study Completion	2027-02-10 (estimated)
Updated on ClinicalTrials.gov	2026-09-03